August 22, 2025Blood AdvancesOpen Access

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

View Full Paper

Ask AI

Bookmark

Authors

NSNirav N. ShahMedical College of Wisconsin PZPier Luigi ZinzaniIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola MWMichael WangCreighton University

Discussion

Member takes

Implication

Phase 1/2 trial found pirtobrutinib achieved 50% overall response rates in heavily pre-treated R/R follicular lymphoma patients, indicating its potential efficiency.

Key Points

Pirtobrutinib demonstrated a 50% overall response rate in relapsed/refractory follicular lymphoma patients.
The study reported a median duration of response of 5.5 months and a median progression-free survival of 5.8 months.
This was a phase 1/2 trial assessing safety and efficacy of pirtobrutinib in a cohort of 48 patients.
Pirtobrutinib was well tolerated, with only 4.2% of patients discontinuing treatment due to adverse events.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/68af707c7567bf4f94fec7d3 https://doi.org/10.1182/bloodadvances.2024014975

View Full Paper

Ask AI

Bookmark

Implication

Phase 1/2 trial found pirtobrutinib achieved 50% overall response rates in heavily pre-treated R/R follicular lymphoma patients, indicating its potential efficiency.

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider